Presentations

A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration.

Berkhout J., Fairman D., Noort van Noort, and Steeg van T.J. A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration. PAGE 2024 [Link to publication]

Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia.

Goulooze S.C., Yang S, Mesic E, Beerahee M, Post T.M, Mahar K.M. Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]

Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat).

Goulooze S.C., Noort van M., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat). PAGE 2023 [Link to publication]

Two New User-Friendly Approaches to Assess Pharmacometric Model Identifiability.

Noort van M., DeJongh J. Two New User-Friendly Approaches to Assess Pharmacometric Model Identifiability. PAGE 2023 [Link to publication]

Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight.

Bosch R., Snelder N. Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight. PAGE 2023 [Link to publication]

Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients.

Marostica E., Ahsman M., Van Bragt T., Noukens J., T’joen C., Ulrichts P., Vis P., Rossenu S., Steeg van T. Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients. PAGE 2023 [Link to publication]

Development of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making.

Struemper H., Rathi C., Muliaditan M., Goulooze S.C., Mantero A., Post T.M., Visser S.A.G. Development of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making. PAGE 2023 [Link to publication]

Conditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making.

Goulooze S.C., Muliaditan M., Mantero A., Visser S.A.G., Post T.M., Rathi C., Struemper H. Conditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making. PAGE 2023. [Link to publication]

Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia.

Noort van M., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]

A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables.

Fu Y., Guo T., Taghvafard H., Said M.M., Demeester C., Dudal V., Graaf van der P.H., Snelder N., Hasselt  van C.J.G. A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables. PAGE 2022 [Link to publication]

Expertise

Categories